FineImmune Biotechnology is a startup based in China.
Based in China, FineImmune Biotechnology is a startup.
FineImmune Biotechnology is a T cell therapy company focused on solving technical bottlenecks in the tumor microenvironment (TME). It has discovered proprietary biomarkers, such as CXCL13, intended as targets for anti-cancer cell therapies including TAL, personalized TCRT and CART.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.